Literature DB >> 31296571

Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression.

Vinay Mandati1, Laurence Del Maestro1, Florent Dingli2, Bérangère Lombard2, Damarys Loew2, Nicolas Molinie3, Stephane Romero3, Daniel Bouvard4, Daniel Louvard1, Alexis M Gautreau3, Eric Pasmant5, Dominique Lallemand6.   

Abstract

Although Merlin's function as a tumor suppressor and regulator of mitogenic signaling networks such as the Ras/rac, Akt, and Hippo pathways is well-documented, in mammals as well as in insects, its role during cell cycle progression remains unclear. In this study, using a combination of approaches, including FACS analysis, time-lapse imaging, immunofluorescence microscopy, and co-immunoprecipitation, we show that Ser-518 of Merlin is a substrate of the Aurora protein kinase A during mitosis and that its phosphorylation facilitates the phosphorylation of a newly discovered site, Thr-581. We found that the expression in HeLa cells of a Merlin variant that is phosphorylation-defective on both sites leads to a defect in centrosomes and mitotic spindles positioning during metaphase and delays the transition from metaphase to anaphase. We also show that the dual mitotic phosphorylation not only reduces Merlin binding to microtubules but also timely modulates ezrin interaction with the cytoskeleton. Finally, we identify several point mutants of Merlin associated with neurofibromatosis type 2 that display an aberrant phosphorylation profile along with defective α-tubulin-binding properties. Altogether, our findings of an Aurora A-mediated interaction of Merlin with α-tubulin and ezrin suggest a potential role for Merlin in cell cycle progression.
© 2019 Mandati et al.

Entities:  

Keywords:  Aurora A; Merlin; Merlin/NF2; NF2; cancer biology; cell proliferation; ezrin; isoforms; mitosis; neurofibromatosis type 2; phosphorylation; tubulin; tumor suppressor gene

Mesh:

Substances:

Year:  2019        PMID: 31296571      PMCID: PMC6721933          DOI: 10.1074/jbc.RA118.006937

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

Review 1.  ERM proteins and merlin: integrators at the cell cortex.

Authors:  Anthony Bretscher; Kevin Edwards; Richard G Fehon
Journal:  Nat Rev Mol Cell Biol       Date:  2002-08       Impact factor: 94.444

2.  Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein.

Authors:  M Giovannini; E Robanus-Maandag; M Niwa-Kawakita; M van der Valk; J M Woodruff; L Goutebroze; P Mérel; A Berns; G Thomas
Journal:  Genes Dev       Date:  1999-04-15       Impact factor: 11.361

3.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

4.  Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin.

Authors:  J J Meng; D J Lowrie; H Sun; E Dorsey; P D Pelton; A M Bashour; J Groden; N Ratner; W Ip
Journal:  J Neurosci Res       Date:  2000-11-15       Impact factor: 4.164

5.  Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin.

Authors:  Taru Muranen; Mikaela Grönholm; G Herma Renkema; Olli Carpén
Journal:  Oncogene       Date:  2005-02-10       Impact factor: 9.867

6.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

7.  A functional association between merlin and HEI10, a cell cycle regulator.

Authors:  M Grönholm; T Muranen; G G Toby; T Utermark; C O Hanemann; E A Golemis; O Carpén
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

8.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.

Authors:  Dominique Lallemand; Marcello Curto; Ichiko Saotome; Marco Giovannini; Andrea I McClatchey
Journal:  Genes Dev       Date:  2003-04-14       Impact factor: 11.361

9.  Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.

Authors:  Joseph L Kissil; Erik W Wilker; Kristen C Johnson; Matthew S Eckman; Michael B Yaffe; Tyler Jacks
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

10.  Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin.

Authors:  Bruno T Fievet; Alexis Gautreau; Christian Roy; Laurence Del Maestro; Paul Mangeat; Daniel Louvard; Monique Arpin
Journal:  J Cell Biol       Date:  2004-03-01       Impact factor: 10.539

View more
  3 in total

Review 1.  The Hippo Signaling Pathway in Drug Resistance in Cancer.

Authors:  Renya Zeng; Jixin Dong
Journal:  Cancers (Basel)       Date:  2021-01-16       Impact factor: 6.639

Review 2.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.

Authors:  Ruijuan Du; Chuntian Huang; Kangdong Liu; Xiang Li; Zigang Dong
Journal:  Mol Cancer       Date:  2021-01-15       Impact factor: 27.401

Review 3.  The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective.

Authors:  Yi Xiao; Jixin Dong
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.